Leaders from the trial tech provider discuss how human-focused technology on eClinical platforms can tackle inefficiencies associated with traditional studies.
The StudyTeam Diversity Reporting feature is intended to aid sites and sponsors measure their efforts to reach patients from underrepresented communities.
This month’s launches, expanded facilities, partnerships, and other news includes items from Veeva, Hovione, Florence, Medidata, and other notable firms.
According to data released by the company, the majority of study professionals plan to run agile or hybrid trials over the course of the next 12 months.
According to the pharma firm, Saphnelo (anifrolumab) combined with standard therapy resulted in reduction of systemic lupus erythematosus disease activity.
The firm is investigating viability of voriconazole inhalation powder, intended to treat and prevent invasive pulmonary aspergillosis in asthma patients.
The pharma company has completed enrollment of amyotrophic lateral sclerosis patients in its study investigating drugs like verdiperstat, an oral treatment.
During our November 17 webinar Patient-centric solutions, a group of professionals representing a range of perspectives will share ideas and innovations.
The decentralized tech specialist has acquired Digital Artefacts, a research tech firm focused on cognitive, behavioral, and physiological data capture.
After 30 years’ experience, including stints advising top pharma firms, the expert has joined a firm offering tech aimed at elevating patient ID and enrollment.
The group is collaborating with AbbVie, Janssen, Novartis, Pfizer, and UCB to help advance nocturnal scratch as a digital endpoint for atopic dermatitis.
The company is joining with the Thrombosis Research Institute on the creation of a heart disease patient dataset to advance precision medicine development.
The trial will evaluate a weekly regimen of islatravir and lnecapavir in HIV patients who are virologically suppressed while on antiretroviral therapies.
The cloud software firm’s Digital Clinical Trials Survey Report reveals that the industry is adapting to challenges caused by COVID-19 and other factors.
